Sep. 25, 2014
EPIRUS Biopharmaceuticals, Inc., a Boston- based biopharmaceutical company announced on September 25, 2014 that it has signed a royalty-bearing, multi-product collaboration agreement with Livzon Mabpharm Inc. (Livzon), a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs.
Livzon was also a principal investor in the $36 million private financing round EPIRUS closed in April 2014, prior to becoming a public company.
Under the terms of the agreement, EPIRUS and Livzon will work together to develop, manufacture, and commercialize up to five biosimilar products. The first collaboration product is EPIRUS' Remicade biosimilar BOW015 (infliximab), which was recently approved in India. Livzon will conduct any additional development work necessary for the approval of BOW015 in China and Taiwan.